USANA Health Sciences (USNA) Stock Analysis & AI Equity Report

Packaged Foods USD Explore free reports

USANA Health Sciences (USNA) overview

USANA Health Sciences (USNA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 925m and operating profit of USD 37.4m; the year-end share price was 19.44 USD and market capitalisation was USD 355m. USANA Health Sciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get USANA Health Sciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 533mFY 2025
Share price19.44 USDFY 2025 year end
RevenueUSD 925mFY 2025
Operating profitUSD 37.4mFY 2025
Net earningsUSD 10.8mFY 2025
Market capitalisationUSD 355mFY 2025 year end

About USANA Health Sciences

USANA develops and manufactures nutritional supplements, functional foods, and personal care products, including skincare products. It sells through direct selling, direct-to-consumer, third-party marketplace, and retail channels. Its core nutritional customers include independent Brand Partners who distribute products and Preferred Customers who purchase for personal use. Its Hiya business sells children's health and wellness products directly to consumers.

Generate the USANA Health Sciences report

USANA Health Sciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for USANA Health Sciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on USANA Health Sciences

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.